Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Ho-Yeong Lim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee
Cancer Res Treat. 2009;41(1):12-18.   Published online March 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.1.12
AbstractAbstract PDFPubReaderePub
Purpose

Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.

Materials and Methods

One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1~5 every 4 weeks.

Results

At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.

Conclusion

Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.

Citations

Citations to this article as recorded by  
  • The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
    Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
    Cancer Research and Treatment.2025; 57(1): 39.     CrossRef
  • Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
    Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
    Chemical Physics Letters.2024; 842: 141191.     CrossRef
  • Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
    S. Shruthi, K. Bhasker Shenoy
    ChemistrySelect.2024;[Epub]     CrossRef
  • Recent Advances on Pt-Based Compounds for Theranostic Applications
    Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
    Molecules.2024; 29(15): 3453.     CrossRef
  • Hallmarks of anticancer and antimicrobial activities of corroles
    Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
    Drug Resistance Updates.2023; : 100931.     CrossRef
  • Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
    Dobrina Tsvetkova, Stefka Ivanova
    Molecules.2022; 27(8): 2466.     CrossRef
  • Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
    Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
    Coordination Chemistry Reviews.2022; 472: 214790.     CrossRef
  • Metalofármacos en la terapia contra el cáncer
    Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
    TECNOCIENCIA Chihuahua.2022; 16(3): e1010.     CrossRef
  • Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Dan Gibson
    Journal of Inorganic Biochemistry.2021; 217: 111353.     CrossRef
  • Monofunctional Platinum(II) Anticancer Agents
    Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
    Pharmaceuticals.2021; 14(2): 133.     CrossRef
  • Pt(IV) Prodrugs with NSAIDs as Axial Ligands
    Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
    International Journal of Molecular Sciences.2021; 22(8): 3817.     CrossRef
  • Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Dan Gibson
    Journal of Inorganic Biochemistry.2019; 191: 77.     CrossRef
  • TOXview: a novel graphical presentation of cancer treatment toxicity profiles
    Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Acta Oncologica.2019; 58(8): 1138.     CrossRef
  • Photoactivated platinum-based anticancer drugs
    Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
    Coordination Chemistry Reviews.2018; 376: 405.     CrossRef
  • Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
    Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
    Cancer Chemotherapy and Pharmacology.2018; 81(6): 981.     CrossRef
  • An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
    Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
    Management Science.2016; 62(5): 1511.     CrossRef
  • Platinum(iv) anticancer prodrugs – hypotheses and facts
    Dan Gibson
    Dalton Transactions.2016; 45(33): 12983.     CrossRef
  • Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
    Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
    Journal of Inorganic Biochemistry.2016; 162: 109.     CrossRef
  • VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
    Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
    Molecular Pharmaceutics.2016; 13(11): 3712.     CrossRef
  • Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
    Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
    AIP Advances.2014;[Epub]     CrossRef
  • Nanocarriers for delivery of platinum anticancer drugs
    Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
    Advanced Drug Delivery Reviews.2013; 65(13-14): 1667.     CrossRef
  • Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
    Investigational New Drugs.2012; 30(3): 1224.     CrossRef
  • Cellular interactions of platinum drugs
    Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
    Inorganica Chimica Acta.2012; 393: 75.     CrossRef
  • What do we know about the reduction of Pt(IV) pro-drugs?
    Ezequiel Wexselblatt, Dan Gibson
    Journal of Inorganic Biochemistry.2012; 117: 220.     CrossRef
  • Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
    X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
    European Journal of Surgical Oncology (EJSO).2011; 37(6): 466.     CrossRef
  • The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
    Dalton Transactions.2010; 39(35): 8113.     CrossRef
  • 12,120 View
  • 114 Download
  • 26 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP